Medicofarma Biotech (WAR:MDB) Beneish M-Score: 6.33 (As of Jun. 25, 2026)


WAR:MDB Medicofarma Biotech SA WAR:MDB
28 GF Score
Price zł0.45
GF Value zł0.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medicofarma Biotech Beneish M-Score?

Medicofarma Biotech WAR:MDB 28 Beneish M-Score is 6.33 as of Jun. 25, 2026. GuruFocus rates WAR:MDB with a GF Score™ of 28/100 and a GF Value™ of zł0.05 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 911 Drug Manufacturers companies, Medicofarma Biotech ranks worse than 97.91% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 6.33 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Medicofarma Biotech's Beneish M-Score or its related term are showing as below:

WAR:MDB' s Beneish M-Score Range Over the Past 10 Years
Min: -11.12   Med: -2.11   Max: 16.12
Current: 6.33

During the past 13 years, the highest Beneish M-Score of Medicofarma Biotech was 16.12. The lowest was -11.12. And the median was -2.11.


Medicofarma Biotech Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Medicofarma Biotech's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicofarma Biotech Beneish M-Score Chart

Medicofarma Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.69 -3.09 2.58 -2.52 6.33

Medicofarma Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 6.33 0.00

WAR:MDB vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicofarma Biotech Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Medicofarma Biotech's Beneish M-Score falls into.


WAR:MDB
28GF Score
Medicofarma Biotech SA WAR:MDB
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicofarma Biotech Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Medicofarma Biotech for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 13.6192+0.528 * -1.3847+0.404 * 0.1426+0.892 * 0.098+0.115 * 0.9552
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * -0.087798-0.327 * 0.9292
=6.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was zł5.08 Mil.
Revenue was zł0.12 Mil.
Gross Profit was zł-0.07 Mil.
Total Current Assets was zł5.11 Mil.
Total Assets was zł14.20 Mil.
Property, Plant and Equipment(Net PPE) was zł9.04 Mil.
Depreciation, Depletion and Amortization(DDA) was zł1.40 Mil.
Selling, General, & Admin. Expense(SGA) was zł0.00 Mil.
Total Current Liabilities was zł4.28 Mil.
Long-Term Debt & Capital Lease Obligation was zł0.00 Mil.
Net Income was zł-2.23 Mil.
Gross Profit was zł0.00 Mil.
Cash Flow from Operations was zł-0.98 Mil.
Total Receivables was zł3.80 Mil.
Revenue was zł1.23 Mil.
Gross Profit was zł1.05 Mil.
Total Current Assets was zł3.81 Mil.
Total Assets was zł14.71 Mil.
Property, Plant and Equipment(Net PPE) was zł10.56 Mil.
Depreciation, Depletion and Amortization(DDA) was zł1.55 Mil.
Selling, General, & Admin. Expense(SGA) was zł0.00 Mil.
Total Current Liabilities was zł4.78 Mil.
Long-Term Debt & Capital Lease Obligation was zł0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5.075 / 0.12) / (3.804 / 1.225)
=42.291667 / 3.105306
=13.6192

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.046 / 1.225) / (-0.074 / 0.12)
=0.853878 / -0.616667
=-1.3847

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5.113 + 9.044) / 14.203) / (1 - (3.812 + 10.564) / 14.71)
=0.003239 / 0.022706
=0.1426

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.12 / 1.225
=0.098

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.548 / (1.548 + 10.564)) / (1.397 / (1.397 + 9.044))
=0.127807 / 0.133799
=0.9552

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 0.12) / (0 / 1.225)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 4.284) / 14.203) / ((0 + 4.775) / 14.71)
=0.301626 / 0.324609
=0.9292

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-2.231 - 0 - -0.984) / 14.203
=-0.087798

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Medicofarma Biotech has a M-score of 6.33 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 6.33 mean?
Medicofarma Biotech (WAR:MDB) has a Beneish M-Score of 6.33 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Medicofarma Biotech and its competitors. According to the industry distribution chart, Medicofarma Biotech ranks #892 out of 911 companies in the Drug Manufacturers industry, placing it in the top 97.9%.
Is Medicofarma Biotech's Beneish M-Score too high?
Medicofarma Biotech's current Beneish M-Score is 6.33. Based on the distribution chart, Medicofarma Biotech ranks #892 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicofarma Biotech has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicofarma Biotech ranks #892 out of 911 companies for Beneish M-Score. This places Medicofarma Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Medicofarma Biotech and its competitors. Medicofarma Biotech's current Beneish M-Score is 6.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.05, compared to a current price of zł0.45 — trading 792% above its estimated fair value. The current Beneish M-Score is 6.33. Medicofarma Biotech's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Beneish M-Score is 6.33 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?

Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued. The current stock price of zł0.45 is trading 792% above its estimated GF Value™ of zł0.05. GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.

Key valuation signals for WAR:MDB:

  • Beneish M-Score: 6.33
  • GF Value™: zł0.05 vs. price of zł0.45 (792% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medicofarma Biotech Business Description

Address ul. Sokołowska 9 lok. U19, Warsaw, POL, 01-142
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
28GF Score

Get the complete analysis for WAR:MDB

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.45
Price
zł0.05
GF Value